POWERFUL NEWS:

MMRF PRESS RELEASES


Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation (MMRF), Receives Honorary Degree from The University of Vermont (UVM)


Honorary Degree Recognizes her Leadership in Cancer Research

Norwalk, CT — May 21, 2013

The Multiple Myeloma Research Foundation (MMRF) is honored to announce that Kathy Giusti, MMRF Founder and CEO, was presented with an Honorary Doctor of Humane Letters degree from The University of Vermont (UVM) on Sunday May 19, 2013. UVM celebrated its 211th commencement and presented five outstanding individuals with honorary degrees at the University Commencement Main Ceremony.

“I am truly proud to be recognized by my undergraduate alma matter, The University of Vermont, with the Honorary Doctor of Humane Letters degree,” said Giusti. “My studies at UVM started my path in the scientific field that would ultimately inspire me to develop innovative approaches to speed cancer research.”

In 1980, Giusti graduated from UVM, magna cum laude, with a degree in biology. Five years later, she received her MBA at Harvard Business School and launched a career in the pharmaceutical industry. After her diagnosis with multiple myeloma, Giusti took her business acumen and scientific background, and dedicated her life to accelerating new treatments and ultimately a cure for this disease. Under her leadership as Founder and CEO, the MMRF has raised more than $225 million for research, which has led to the MMRF being instrumental in bringing patients six new FDA-approved treatments in the last decade, which is nearly unprecedented in oncology; these treatments have helped to more than double the life expectancy of myeloma patients.

“Giusti remains that hopeful mother, a cancer patient in remission on a mission,” wrote journalist Rick Green in a recent profile featured in Vermont Quarterly. “This is what drives her—and what is helping to change the way cancer will be cured.”

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 41 percent, one of the lowest of all cancers. In 2013, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $225 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 10 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.

Media contacts:
MMRF
Anne Quinn Young
203-536-8691
QuinnYoungA@themmrf.org